Octagon Capital Advisors LP
In its 13F for Q2 2026 (holdings as of June 30, 2026, filed August 14, 2026), Octagon Capital Advisors LP reported 26 stock positions worth $1.1 billion. Its top holding was Dianthus Therapeutics (DNTH) at 16.5% of the portfolio, followed by Definium Therapeutics (DFTX, 12.7%) and Abivax SA-ADR (ABVX, 12.1%). Compared with Q1 2026, it opened 4 new positions, sold out of 7, added to 4 and reduced 6. The biggest buy was Definium Therapeutics (DFTX, shares +21%) and the biggest sale an exit from Centessa Pharmaceuticals (CNTA).
- Most Recent 13F
- Q2 2026
- Location
- NEW YORK, NY
- CIK
- 0001839435
- Portfolio Value
- $1.1B (Q2 2026)
- SEC Filing
- 0001839435-26-000004 ↗ filed Aug 14, 2026
Holdings Value
Holdings 26 stocks · $1.1B
| DNTH Dianthus Therapeutics Inc. | 16.48% | 1,841,667 | $179.5M | Reduce -5.4% |
| DFTX Definium Therapeutics Inc. | 12.74% | 2,950,000 | $138.8M | Add +20.9% |
| ABVX Abivax SA-ADR | 12.15% | 993,000 | $132.3M | Add +46.7% |
| COGT Cogent Biosciences Inc. | 8.35% | 2,350,000 | $90.9M | No change |
| ALMS Alumis Inc. | 7.31% | 2,830,700 | $79.7M | No change |
| AVBP Arrivent Biopharma Inc. | 6.28% | 1,971,054 | $68.5M | No change |
| TSHA Taysha Gene Therapies Inc. | 6.06% | 9,693,244 | $66.0M | Add +9.4% |
| BIOA Bioage Labs Inc. | 3.93% | 1,748,000 | $42.8M | No change |
| MIRM Mirum Pharmaceuticals Inc. | 3.64% | 338,900 | $39.7M | No change |
| KYMR Kymera Therapeutics Inc. | 3.26% | 310,000 | $35.5M | Reduce -27.1% |
| AKTS Aktis Oncology Inc. | 2.84% | 960,847 | $31.0M | No change |
| XENE Xenon Pharmaceuticals Inc. | 2.71% | 490,000 | $29.6M | No change |
| PALI Palisade Bio Inc. | 1.97% | 10,276,317 | $21.5M | No change |
| OCUL Ocular Therapeutix Inc. | 1.87% | 2,075,000 | $20.4M | Reduce -34.5% |
| IRON Disc Medicine Inc. | 1.81% | 270,000 | $19.7M | No change |
| SMMT Summit Therapeutics Inc. | 1.67% | 1,250,000 | $18.2M | New |
| PHVS Pharvaris NV | 1.45% | 456,721 | $15.8M | Add +176.8% |
| ANL Adlai Nortye Group Ltd. | 0.99% | 934,716 | $10.7M | New |
| DTIL Precision Biosciences Inc. | 0.97% | 1,350,000 | $10.6M | Reduce -39.6% |
| DBVT DBV Technologies SA-Spon ADR | 0.86% | 574,200 | $9.4M | No change |
| FTH Faeth Therapeutics Inc. | 0.83% | 361,010 | $9.0M | New |
| GYRE Gyre Therapeutics Inc. | 0.58% | 954,416 | $6.3M | New |
| TRVI Trevi Therapeutics Inc. | 0.54% | 315,000 | $5.9M | Reduce -78.8% |
| UNCY Unicycive Therapeutics Inc. | 0.43% | 1,000,000 | $4.7M | No change |
| CNTX Context Therapeutics Inc. | 0.16% | 3,050,000 | $1.7M | Reduce -41.9% |
| GOSS Gossamer Bio Inc. | 0.12% | 7,750,000 | $1.3M | No change |
Options reported separately and not counted above: ERASCA INC calls ($23.0M).
Portfolio Sells Q1 2026 → Q2 2026
| CNTA Centessa Pharmaceuticals Ltd. | Sold out | 0.00% | −3.30 |
| KALV Kalvista Pharmaceuticals Inc. | Sold out | 0.00% | −3.23 |
| TERN Terns Pharmaceuticals Inc. | Sold out | 0.00% | −3.09 |
| DNTH Dianthus Therapeutics Inc. | Reduce -5.4% | 16.48% | −1.60 |
| TRVI Trevi Therapeutics Inc. | Reduce -78.8% | 0.54% | −1.42 |
| CNTX Context Therapeutics Inc. | Reduce -41.9% | 0.16% | −1.37 |
| OCUL Ocular Therapeutix Inc. | Reduce -34.5% | 1.87% | −1.10 |
| BBOT Bridgebio Oncology Therapeut | Sold out | 0.00% | −0.71 |
| LXEO Lexeo Therapeutics Inc. | Sold out | 0.00% | −0.70 |
| KYMR Kymera Therapeutics Inc. | Reduce -27.1% | 3.26% | −0.65 |
| DTIL Precision Biosciences Inc. | Reduce -39.6% | 0.97% | −0.39 |
| CATX Perspective Therapeutics Inc. | Sold out | 0.00% | −0.37 |
| EVMN Evommune Inc. | Sold out | 0.00% | −0.36 |
Portfolio Buys Q1 2026 → Q2 2026
| DFTX Definium Therapeutics Inc. | Add +20.9% | 12.74% | +7.63 |
| ABVX Abivax SA-ADR | Add +46.7% | 12.15% | +3.80 |
| TSHA Taysha Gene Therapies Inc. | Add +9.4% | 6.06% | +1.68 |
| SMMT Summit Therapeutics Inc. | New | 1.67% | +1.67 |
| ANL Adlai Nortye Group Ltd. | New | 0.99% | +0.99 |
| PHVS Pharvaris NV | Add +176.8% | 1.45% | +0.93 |
| FTH Faeth Therapeutics Inc. | New | 0.83% | +0.83 |
| GYRE Gyre Therapeutics Inc. | New | 0.58% | +0.58 |
Options Activity Q1 2026 → Q2 2026
| ERASCA INC | call | New | 1,255,000 | $23.0M |
Calls and puts are listed by the shares they cover; their value is not part of the stock holdings above.
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 26 | $1.1B | DNTH, DFTX, ABVX, COGT, ALMS |
| Q1 2026 | 29 | $903.6M | DNTH, COGT, ABVX, ALMS, DFTX |
| Q4 2025 | 26 | $798.8M | ABVX, DNTH, COGT, TSHA, GOSS |
| Q3 2025 | 25 | $640.2M | ABVX, DNTH, GOSS, COGT, AVBP |
| Q2 2025 | 29 | $455.3M | DNTH, AVBP, VRNA, TSHA, SPRY |
| Q1 2025Amended | 33 | $460.1M | APLS, DNTH, AVBP, TRVI, CNTA |
| Q4 2024 | 30 | $587.1M | APLS, AVBP, DNTH, CNTA, VRNA |
| Q3 2024 | 40 | $623.9M | APLS, VRNA, GPCR, DNTH, AVBP |
| Q2 2024 | 44 | $606.1M | APLS, DNTH, GPCR, INSM, DYN |
| Q1 2024 | 56 | $822.6M | APLS, ALPN, DNTH, VRNA, DYN |